Dr. Markman on Combination Treatments in Ovarian Cancer

Maurie Markman, MD
Published: Wednesday, Jan 18, 2017



Combination therapies, particularly in the treatment landscape of ovarian cancer, are somewhat complicated, says Markman. Several questions remain regarding whether to administer agents at the same to patients, or to sequence them. If one sequences them, the question becomes: which drug should be given first? Moreover, maintenance approaches require more research, as well.

The good news, he says, is that there are generally not many patients with ovarian cancer, especially compared with the population of patients with lung cancer. While this is considered a good thing, it presents difficulties from a clinical trials perspective, Markman explains. With such a limited population, these lingering questions regarding combination approaches, biomarkers, and more continue to go unanswered.

It is key, then, to develop "great" clinical trials. According to Markman, an optimal clinical trial is one that patients genuinely want to participate in, and is one that will quickly and definitively answer the right questions.


Combination therapies, particularly in the treatment landscape of ovarian cancer, are somewhat complicated, says Markman. Several questions remain regarding whether to administer agents at the same to patients, or to sequence them. If one sequences them, the question becomes: which drug should be given first? Moreover, maintenance approaches require more research, as well.

The good news, he says, is that there are generally not many patients with ovarian cancer, especially compared with the population of patients with lung cancer. While this is considered a good thing, it presents difficulties from a clinical trials perspective, Markman explains. With such a limited population, these lingering questions regarding combination approaches, biomarkers, and more continue to go unanswered.

It is key, then, to develop "great" clinical trials. According to Markman, an optimal clinical trial is one that patients genuinely want to participate in, and is one that will quickly and definitively answer the right questions.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x